Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
03/26/2020 03/27/2020 03/30/2020 03/31/2020 04/01/2020 Date
7.6(c) 8(c) 7.93(c) 8.45(c) 8(c) Last
183 079 191 132 171 738 195 107 111 840 Volume
-0.65% +5.26% -0.88% +6.56% -5.33% Change
More quotes
Financials (EUR)
Sales 2020 36,7 M
EBIT 2020 -130 M
Net income 2020 -119 M
Finance 2020 181 M
Yield 2020 -
Sales 2021 81,0 M
EBIT 2021 -131 M
Net income 2021 -124 M
Finance 2021 93,3 M
Yield 2021 -
P/E ratio 2020 -2,95x
P/E ratio 2021 -3,30x
EV / Sales2020 4,34x
EV / Sales2021 3,04x
Capitalization 340 M
More Financials
Company
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene... 
More about the company
Surperformance© ratings of Cellectis
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLECTIS
03/26CALYXT, INC. : Financial Statements and Exhibits (form 8-K)
AQ
03/11CELLECTIS : US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to C..
AQ
03/10CELLECTIS S A : US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted ..
BU
03/05CALYXT, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
03/04CELLECTIS : Provides Business Update and Reports 4th Quarter and Full Year 2019 ..
BU
03/04CELLECTIS : and Servier Execute the Amendment Confirming the Expansion of Their ..
BU
02/25CELLECTIS TO HOLD FOURTH QUARTER AND : 30 am est
BU
02/19CELLECTIS : and Servier Expand Collaboration on UCART19 Products; Cellectis : gr..
AQ
02/18CELLECTIS : and Servier Expand Collaboration on UCART19 Products
BU
02/05CALYXT, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/21CALYXT, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
01/16CELLECTIS : First Patient Dosed with Cellectis' New Allogeneic UCART123 Product ..
AQ
01/15CELLECTIS S A : First Patient Dosed with Cellectis' New Allogeneic UCART123 Prod..
BU
01/14Allogene Therapeutics and Spring Works Therapeutics Announce Clinical Collabo..
AQ
01/07CELLECTIS : and World Experts Review New Avenue of Allogeneic CAR T-cells, Optim..
AQ
More news
News in other languages on CELLECTIS
03/11EN DIRECT DES MARCHES : Renault, Sanofi, Air France, Boiron, Nicox, Adidas, F..
03/11STOCK MARKET PARIS : Déjà la rechute ?
03/11STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
03/11STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe (actualisé)
03/10CELLECTIS : obtient un brevet aux États-Unis couvrant les cellules CAR-T allogén..
More news
Stock Trading Strategies
CELLECTIS - 2019
A technical turn-around configuration
BUY
More Stock Trading Analysis
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 23,00  €
Last Close Price 8,00  €
Spread / Highest target 219%
Spread / Average Target 188%
Spread / Lowest Target 156%
EPS Revisions
Managers
NameTitle
André Choulika Chairman & Chief Executive Officer
Elsy Boglioli Chief Operating Officer
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Stephane Depil Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS-48.98%394
LONZA GROUP13.87%31 009
CELLTRION, INC.22.13%25 160
IQVIA HOLDINGS INC.-35.25%20 797
SEATTLE GENETICS, INC.-2.64%19 875
INCYTE CORPORATION-16.14%15 874